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The use of clostridium botulinum toxin in palatal myoclonus.
A preliminary report
SHAKEEL R. SAEED F.R.C.S., GERALD B. BROOKES F.R.C.S. (London)
Abstract
Palatal myoclonus is a rare syndrome characterized by involuntary rhythmical movements of the soft palate
giving rise to clicking objective tinnitus. The intrusive nature of the tinnitus prompts patients to seek medical
advice but to date no single treatment modality has been shown to be consistently effective. We present three
cases in whom various management regimes were unsuccessful and in whom botulinum toxin injection to the
palatal muscles was undertaken. All three cases were rendered free of their tinnitus with complete abolition of
the myoclonus. The questions of optimum dosage as well as frequency of injection will be answered as greater
numbers are treated by this method.
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Introduction
The tinnitus associated with palatal myoclonus has been
traditionally managed with drugs such as anxiolytics,
antidepressants and anticonvulsants or surgical proce-
dures aimed at modifying palatal and eustachian tube
function as well as adjunctive measures such as psycho-
therapy. The tinnitus however is often refractory to these
measures though more recently white-noise masking has
shown more favourable results in selected cases. We
describe an alternative treatment modality aimed at abol-
ishing the myoclonic activity by selective injection of the
palatal muscles with botulinum toxin.
Case reports
Case 1
A 25-year-old male presented initially with right-sided
headaches, blurred vision, episodic dysphagia and click-
ing in both ears. General and neurological examination
was unremarkable and investigations including computer-
ized tomography of the head were normal. Following
psychiatric assessment and treatment with an anxiolytic
drug the patient's headaches resolved.
The tinnitus however persisted and otological appraisal
confirmed an audible clicking noise emanating from the
right side of the face. Flexible nasendoscopy with topical
anaesthesia showed bilateral myoclonic activity of the
soft palate synchronous with the audible bruit. Pure tone
audiometry and tympanometry were normal and having
explained the findings to the patient five mouse-units of
botulinum toxin were injected into both sides of the soft
palate. Outpatient review at four and twelve weeks
showed the patient to be free of his tinnitus with no
untoward effects.
Case 2
A 64-year-old female presented for consideration of
botulinum toxin injection for palatal myoclonus. She had
suffered intractable clicking noises in her head for twelve
years that were often of sufficient intensity to be heard by
her husband. The original somewhat speculative diagnosis
of minor brainstem vascular accident had been managed
with benzodiazepines. The tinnitus was refractory to treat-
ment with various antidepressants and anticonvulsants as
well as physiotherapy and relaxation exercises.
On examination the patient had easily audible tinnitus
in time with the visible rhythmical movements of the soft
palate. Five mouse-units of botulinum toxin were injected
into the soft palate bilaterally and the myoclonus abated
for a few hours. Repeated injections on two subsequent
occasions had a similar effect but a fourth injection of fif-
teen mouse-units resulted in marked nasal regurgitation.
and dysphagia with minimal improvement in the tinnitus.
The adverse effects resolved completely in four weeks but
the tinnitus persisted.
Three months later the patient requested a further trial
of injection therapy and gained a marked improvement in
her tinnitus with no side-effects following injection of ten
mouse-units of the toxin into the palate bilaterally.
Case 3
A 70-year-old female had suffered with palatal myo-
clonus and intrusive tinnitus for seven years. Initial inves-
tigations including cerebrocervical angiography had been
negative. Antidepressants and anxiolytic drugs were
unhelpful and indeed the only medication that had given
any relief was carbamazepine but unfortunately the
patient developed a cutaneous sensitivity reaction neces-
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sitating withdrawal of the drug. Subsequent treatment
with white-noise masking, eustachian tube diathermy and
even hamulectomy had been unfruitful. On this basis the
patient was referred for botulinum toxin injection and ten
mouse-units were injected bilaterally into the palatal
muscles.
The patient reported some initial difficulty with swal-
lowing and speech secondary to palatal weakness but the
myoclonus and the associated tinnitus were abolished.
This state of remission was maintained for one year and
repeat injection with five mouse-units bilaterally allowed
the patient to remain free of the myoclonus.
Discussion
Palatal myoclonus is a rare but increasingly reported
syndrome characterized by involuntary rhythmical move-
ments of the soft palate, usually bilaterally, with clonic
rates of 40 to 240 per minute. The condition was first
reported in 1873 by Kupper though Spencer coined the
phrase 'pharyngeal and laryngeal mystagmus' (Spencer,
1886). The objective clicking tinnitus associated with the
myoclonic contractions had already been noted by Pol-
itzer in 1887 who postulated that the snapping shut of the
eustachian tube following tubal opening by the actions of
the palatine muscles gave rise to the clicking noises
(Samant et al., 1970). The condition is considered as a dis-
turbance of cerebello-medullary neural function and may
be associated with myoclonic activity in the pharyngeal,
laryngeal, ocular and diaphragmatic muscles. Cases have
been observed following blunt and penetrating trauma to
the head and neck, infective inflammatory conditions such
as viral encephalitis, malaria and syphilis, demyelinating
diseases, aneurysms of the vertebral artery, posterior fossa
tumours as well as in heredofamilial tremor. Seventy per
cent of cases however are secondary to vascular infarcts
(Fitzgerald, 1984). Whilst no specific nervous pathway or
nuclear lesion has been definitively implicated various
studies have traced the pathogenesis to an area consisting
of the dentate nucleus, red nucleus and the inferior olivary
nucleus, collectively constituting the Guillain-Mollaret
triangle (Siegel, 1987). Further refinements have demon-
strated hypertrophic degeneration of the contralateral
inferior olivary nucleus, the whole area being referred to
as the myoclonic triangle (Lapresle, 1979). Experimental
injury to the inferior olive in monkeys has produced the
characteristic myoclonus adding further evidence to this
neurological localization (Fitzgerald, 1984).
Investigation of patients presenting with palatal myo-
clonus aims at excluding causes such as those cited earlier
before terming a case as idiopathic. In particular, pure
tone and evoked response audiometry with tympanometry
to exclude middle and inner ear disorders as well as mag-
netic resonance imaging of the posterior fossa and brain-
stem should be undertaken.
Numerous treatment modalities have been used in an
attempt to abolish the often incapacitating tinnitus that
these patients suffer. None has been shown conclusively
to confer lasting benefit. Therapeutic regimes including
anxiolytic, antidepressant and anticonvulsant drugs have
yielded varying results as have physiotherapy, acupunc-
ture, relaxation exercises and hypnosis. Attempts at top-
ical and infiltrative local anaesthesia have been unfruitful
as have surgical procedures such as palatal muscle section
and tenotomy of the muscles of the middle ear cleft. More
recently, the results of white-noise masking in selected
cases have been encouraging, indeed eleven out of twelve
patients treated this way gained some benefit with three
patients being rendered symptom free. The source of the
actual clicking is postulated to arise from the breakdown
of fluid surface tension as the walls of the eustachian tube
open under the action of the peritubal muscles (East and
Hazell, 1987). The myoclonus however is characteristi-
cally resistant to current methods of treatment and we con-
sidered that local botulinum toxin injections may confer
benefit.
Clostridium botulinum toxin is a protein which, if
injected into a muscle selectively weakens it. The toxin
binds to the motor end-plate and prevents acetylcholine
release giving rise to pre-synaptic neuromuscular block-
ade. This leads to atrophy and weakness of the muscle
which can last between two to twenty days though recov-
ery by formation of new terminal axons can take up to four
months. The actual doses used are related to the muscle
bulk to be weakened and further injections are titrated
against the response (Moore, 1991). The drug is a non-
infectious toxin-haemagglutinin complex and whilst six
toxin serotypes have been isolated only type A is in clini-
cal use. The potency is standardised in mouse LD50 units
Site of injection
^ Insertion of Levator Veli Palatini
^ Insertion and aponeurosis of
Tensor Veli Palatini
FIG. 1
Schematic diagram to show the site of injection of the botulinum
toxin.
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with 40 mouse-units corresponding to 1 ng of UK toxin-
haemagglutinin complex. (Mountain et al., 1992). The
drug already has an established role in the management of
hemifacial spasm and focal blepharospasm for which it is
licenced and is being increasingly used for spasmodic tor-
ticollis, strabismus and oromandibular dystonias. Our
department has considerable clinical experience in the
treatment of both adductor and abductor spasmodic laryn-
geal dystonias using this agent with good long term
results. Side-effects are generally minor and attributable
to transient weakness of muscles affected by local spread
of the toxin. Usage in children has not been evaluated
(Marsden and Quinn, 1990).
To our knowledge botulinum toxin has not been used
previously in the treatment of palatal myoclonus. The
three cases described illustrate how current treatment
modalities can be exhausted leaving the patient with
intractable intrusive tinnitus. The patients were offered
toxin injection after having explained the potential bene-
fits and inherent side-effects of such treatment. The drug
is injected posteromedial to the maxillary tuberosity in an
attempt to paralyse the levator and tensor veli palatini
muscles which are the prime openers of the eustachian
tube (Fig. 1). Two of the cases gained marked benefit from
the treatment with abolition of the myoclonus for several
months. Case 2 however required repeated injections and
illustrated that one cannot invariably expect a favourable
outcome and indeed the local side-effects may initially
detract from continuing treatment. Further evaluation is
required, in particular to establish optimal doses and
injection frequency and hopefully this information will
become available as more patients are treated by this
means.
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